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ABSTRACT
Meiosis arrest female 1 (MARF1) is a cytoplasmic
RNA binding protein that is essential for meiotic pro-
gression of mouse oocytes, in part by limiting retro-
transposon expression. MARF1 is also expressed in
somatic cells and tissues; however, its mechanism of
action has yet to be investigated. Human MARF1 con-
tains a NYN-like domain, two RRMs and eight LOTUS
domains. Here we provide evidence that MARF1 post-
transcriptionally silences targeted mRNAs. MARF1
physically interacts with the DCP1:DCP2 mRNA de-
capping complex but not with deadenylation ma-
chineries. Importantly, we provide a 1.7 A˚ resolution
crystal structure of the human MARF1 NYN domain,
which we demonstrate is a bona fide endoribonucle-
ase, the activity of which is essential for the repres-
sion of MARF1-targeted mRNAs. Thus, MARF1 post-
transcriptionally represses gene expression by serv-
ing as both an endoribonuclease and as a platform
that recruits the DCP1:DCP2 decapping complex to
targeted mRNAs.
INTRODUCTION
mRNA degradation is a key process in post-transcriptional
regulation of gene expression. One of the major mRNA
turnover pathways in eukaryotes initiates with the removal
of the mRNA 3′ poly(A) tail by the CCR4-NOT deadeny-
lase complex (1). This is then followed by recruitment of
the DCP1:DCP2 decapping complex that hydrolyzes the
mRNA5′-cap structure and commits a transcript for degra-
dation by the 5′-to-3′ exonuclease XRN1 (2). RNA decay
proteins localize to processing (P) bodies, discrete cytoplas-
mic foci that contain the CCR4-NOT complex, as well as
decapping proteins including DCP1 and DCP2 (3). The
CCR4-NOT deadenylase complex is recruited to targeted
mRNAs by a number of gene silencing factors, including
the microRNA-induced silencing complex (miRISC) or by
RNA-binding proteins, such as TTP (4–9).
While deadenylation most often precedes mRNA de-
capping, examples do exist of mRNAs that undergo
deadenylation-independent degradation. For example, it
has been reported to that the yeast ribosomal protein
Rps28b recruits the decappingmachinery to its ownmRNA
to bring about decapping in the absence of deadenylation
(10). Nonsense mediated decay (NMD) in yeast can also
initiate deadenylation-independent decapping followed by
mRNA decay (11–13).
Meiosis arrest female 1 (MARF1) is a large protein
(1742 aa) that has been shown to be critical for regulat-
ing meiotic progression in mouse oocytes (14,15) (Figure
1A). MARF1-null oocytes accumulate Ppp2cb mRNA, the
catalytic beta subunit of the major cellular phosphatase
PP2A, and specific retrotransposon RNAs, including Long
interspersed elements (LINE1) RNA. In addition to its
expression in the mammalian germline, MARF1 is also
expressed in somatic tissues, including in the developing
cerebral cortex where it has been reported to promote
neuronal differentiation (16). Notwithstanding the critical
role MARF1 plays in mammalian oogenesis, the molecu-
lar mechanism underpinning MARF1 function is not un-
derstood. Human MARF1 contains two RNA-recognition
motif (RRM) domains, and eight minimal LOTUS do-
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Figure 1. MARF1 interacts with the DCP1:DCP2mRNA decapping complex. (A) Schematic diagram of full-lengthMARF1. (B) Dot plot depicting high-
confidence protein interactions identified by affinity purification of FLAG-MARF1 in HEK293 cells. SAINT analysis of two independent experiments
was performed and a subset of high-confident preys is presented in this dot plot. Node color represents the average spectral counts, and the node edge
color corresponds to the SAINTexpress Bayesian FDR value (BFDR). (C) Western blot analysis of lysates derived from HEK293 cells expressing either
FLAG-BirA* orFLAG-BirA*-MARF1 and probedwith anti-FLAGantibody. (D) Immunoprecipitation (IP) of FLAG-BirA* andFLAG-BirA*-MARF1
from benzonase–treated HEK293 cell extracts using anti-FLAG antibody. Immunoprecipitated complexes were separated by SDS-PAGE and probed with
antibodies against the indicated proteins. (E) Streptavidin pulldowns of biotinylated proteins from benzonase-treated lysates outlined in (C). Precipitated
proteins were subjected to SDS-PAGE and probed with antibodies against the indicated endogenous proteins. Inputs represent 2% of total lysates.
mains (Figure 1A). It additionally contains a predicted
Nedd4BP1 (N4BP1), YacP-like Nuclease (NYN)-like do-
main. Whether the MARF1 NYN domain exhibits ribonu-
clease activity has not been investigated.
Here we present data demonstrating that MARF1 en-
genders deadenylation-independent decay of targeted mR-
NAs, and provide structural and functional insights into its
mechanism of action. Proteomic analysis demonstrates that
MARF1 physically interacts with the DCP1:DCP2 mRNA
decapping complex but does not associate with the PAN2-
PAN3 or CCR4-NOT deadenylase machineries. Interest-
ingly, MARF1 requires its NYN domain, rather than its
DCP1:DCP2-interacting motif, in order to degrade a tar-
geted reporter mRNA. We report the crystal structure of
the NYN domain, which adopts a PIN (PilT N-terminus)
domain-like fold. Furthermore, we show that the NYN do-
main has intrinsic endoribonuclease activity that can de-
grade single-stranded RNA in vitro, and mutating its cat-
alytic pocket ablates its nuclease activity in vitro and silenc-
ing through MARF1 in vivo. Taken together, our data pro-
vide compelling evidence that human MARF1 is a potent
effector of mRNA silencing in human cells.
MATERIALS AND METHODS
Antibodies
Antibodies against XRN1, PATL1, DCP1, DCP2, EDC4
and DDX6 were from Bethyl Laboratories. CNOT1 anti-
body was from Proteintech. 4E-T antibody was from Ab-
cam. -actin antibody was from Cell Signaling. FLAG,
HA and MYC antibodies were from Sigma, Covance and
Bioshop, respectively.
Cells and transfections
HeLa cells and Flp-In T-REx HEK293 cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum, 50 U/ml penicillin, and
50 g/ml streptomycin. Flp-In T-REx cells were main-
tained in 100 g/ml hygromycin B. All plasmid trans-
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fections were carried out using polyethylenimine (Poly-
sciences).
Plasmids
FLAG-BirA*-MARF1 was generated by Gateway cloning
of pDONR-MARF1 into pcDEST-pcDNA5-BirA*-
FLAG-N-term. Full-length MARF1 and MARF1 frag-
ments were cloned into EcoRI andNotI sites in pCI-NHA
plasmid for tethering experiments. pCI-NHA-LacZ and
reporter plasmids (RL-5BoxB, RL-5BoxB-A114-N40-
HhR and FL) are described previously (17,18). MARF1
fragments were cloned into BamHI and SalI sites of
pBABE-3XFLAG-puro. MARF1 NYN-mutant and
NYN-deletion were generated by site-directed mutagenesis
using Phusion Hot-Start II polymerase.
Affinity purification of FLAG-tagged MARF1 and prepara-
tion for mass spectrometry
Cell lines expressing N-terminally FLAG tagged MARF1
constructs were grown to∼70% confluency in a 15 cm plate,
and the bait expression was induced for 24 h with 2 g/ml
doxycycline. Cells were washed cold in PBS and harvested,
then snap-frozen. The FLAGAP-MS protocol was adapted
from (19) with modifications. Frozen cell pellets were lysed
at a 1:4 (pellet weight in g:lysis buffer volume in ml) ratio in
ice-cold lysis buffer. Lysis buffer contains 50 mM HEPES–
NaOHpH 8.0, 100mMKCl, 2mMEDTA, 0.1%NP40 and
10% glycerol. Protease inhibitors (1:500 Sigma protease in-
hibitor cocktail P8340) were added immediately before use.
Frozen cell pellets were thawed in lysis buffer on ice, resus-
pended by gentle pipetting, and subjected to one cycle of
freeze-thaw (dry ice 5 min/ 37◦C water bath) to aid in ly-
sis. The samples were sonicated at 4◦C using three 10 sec
bursts with 3 s pauses at 30% amplitude. 250 units of ben-
zonase nuclease were added, and the lysates were incubated
at 4◦C for 20 min with rotation. The lysates were then cen-
trifuged at 20 817 g for 20 min at 4◦C and the supernatant
transferred to tubes containing 25 l of 50% magnetic anti-
FLAG M2 beads slurry (Sigma, M8823) pre-washed in ly-
sis buffer. FLAG immunoprecipitation was allowed to pro-
ceed at 4◦C for 2 h and 45 min with rotation. Beads were
pelleted by centrifugation (1000 rpm for 1 min) and magne-
tized, and the unbound lysate was aspirated and kept for
analysis. The beads were demagnetized and washed with
1 ml lysis buffer and magnetized to aspirate off the wash
buffer. The beads were then washed with 1 ml of 20 mM
Tris–HCl (pH 8.0) containing 2 mM CaCl2, and any excess
wash buffer was removed by magnetizing and pipetting off
the liquid. The now-dry magnetic beads were removed from
the magnet and resuspended in 10 l of 20 mM Tris–HCl
(pH 8.0) containing 1 g of trypsin (Sigma, T6567) and the
mixture was incubated at 37◦Cwith agitation overnight. Af-
ter the initial incubation, the beadsweremagnetized and the
supernatant was transferred to a fresh tube. An additional
500 ng of trypsin was added in 2.5 l of 20 mM Tris–HCl
(pH 8.0) and the samples were further incubated, without
agitation, for 4 h. The sample was acidified with formic acid
to a final concentration of 2% and the tryptic digests were
stored at −80◦C until ready for mass spectrometry analysis.
Mass spectrometry acquisition using TripleTOF mass spec-
trometers
A fraction of the digested peptides (5 out of 16 l) was
directly loaded at 400 nl/min onto a 15 cm 100 m ID
emitter tip packed in-house with 3.5 m Reprosil C18 (Dr
Maische). The peptides were eluted from the column at
400 nl/min over a 90 min gradient generated by a 425
NanoLC (Eksigent, Redwood, CA, USA) and analyzed on
a TripleTOF™ 6600 instrument (AB SCIEX, Concord, On-
tario, Canada). The gradient started at 2% acetonitrile with
0.1% formic acid and increased to 35% acetonitrile over 90
min followed by 15min at 80% acetonitrile and 15min at 2%
acetonitrile, for a total of 120 min. To minimize carryover
between each sample, the analytical column was flushed for
1 h with an alternating sawtooth gradient from 35% ace-
tonitrile to 80% acetonitrile, holding each gradient concen-
tration for 5 min at a flow rate of 1500 nl/min. Analyti-
cal column and instrument performance were verified after
each sample by analyzing 30 fmol BSA tryptic peptide di-
gest with 60 fmol -Casein tryptic digest with a short 30
min gradient. MS mass calibration was performed on BSA
reference ions between each sample.
MARF1 AP-MS sample was analyzed in Data Depen-
dent Acquisition (DDA) mode by performing one 250 ms
MS1 TOF survey scan from 400–1250 Da followed by 20×
100 ms MS2 candidate ion scans from 100 to 2000 Da in
high sensitivity mode. Only ions with a charge of 2+ to 4+
that exceeded a threshold of 200 cps were selected for MS2,
and former precursors were excluded for 10 s after one oc-
currence.
MS data analysis
Mass spectrometry data generated were stored, searched
and analyzed using the ProHits laboratory information
management system (20). Raw WIFF files were con-
verted to a MGF format using WIFF2MGF converter
and to an mxML format using ProteoWizard (21). The
searched database contained the human (22) and ade-
novirus complements of the RefSeq protein database
(version 57) supplemented with ‘common contaminants’
from the Max Planck Institute (http://141.61.102.106:8080/
share.cgi?ssid=0f2gfuB) and the Global ProteomeMachine
(GPM; http://www.thegpm.org/crap/index.html) as well as
sequences from common fusion proteins and epitope tags.
The sequence database consisted of forward and reversed
sequences; in total 72 226 sequences were searched. The
search engines were Mascot and Comet, with trypsin speci-
ficity and twomissed cleavage sites allowed.Methionine ox-
idation and asparagine/glutamine deamidation were set as
variable modifications. The fragment mass tolerance was
0.15 Da and the mass window for the precursor was ±35
ppm. The resulting Comet and Mascot search results were
individually processed by PeptideProphet (23), and pep-
tides were assembled into proteins using parsimony rules
first described in ProteinProphet (24) into a final iProphet
(25) protein output using the Trans-Proteomic Pipeline
(TPP; Linux version, v0.0 Development trunk rev 0, Build
201303061711). General TPP options were -p0.05 -x20 -
PPM - d‘DECOY’, iProphet options were pPRIME and
PeptideProphet options were pPAEd. All proteins with a
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minimal iProphet protein probability of 0.05 were parsed
to the relational module of ProHits. Note that for analysis
with SAINT, only proteins with iProphet protein probabil-
ity≥0.95were considered. This corresponds to an estimated
protein level FDR of ∼0.5%. A minimum of two unique
peptide ions was also enforced.
Interaction proteomics scoring using Significance of Analysis
of INTeractome (SAINT)
SAINT calculates, for each prey protein identified in a
purification, the probability of true interaction by using
spectral counting (semi-supervised modelling, using neg-
ative control runs). SAINTexpress (26) analysis was per-
formed using version exp3.3 with two biological replicates
of MARF1-FLAG analyzed alongside six negative control
runs (compressed to four as previously described; 27), con-
sisting of purifications from cells expressing 3xFLAG-GFP,
BirA*-FLAG-GFP or 3xFLAG. All non-human protein
contaminants were removed from the SAINT file.
The proteomics dataset consisting of raw files and asso-
ciated peak list and results files was deposited as a complete
submission in ProteomeXchange (identifier PXD007554)
through partner MassIVE (MSV000081483). This can be
accessed through ftp://massive.ucsd.edu/MSV000081483.
BioID and co-immunoprecipitation experiments
After an over-night incubation in 50 M biotin, cell pel-
lets were either lysed on ice for 1 hour in 500 l of RIPA
buffer containing 50 mM Tris–HCl pH 7.5, 150 mMNaCl,
1% NP-40, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 0.5%
sodium deoxycholate, to which a protease inhibitor cocktail
(aprotinin, leupeptin and pepstatin) and benzonase (50U)
were added immediately before use, or cell pellets were lysed
in 500 l of RIPA buffer at room temperature. Lysates were
sonicated and incubated with streptavidin-coupled Agarose
(Millipore) for 3 h at 4◦C to capture biotinylated proteins.
The beads were then pelleted and if the samples were ini-
tially lysed in RIPA, the beads were washed with 3× 1
ml with RIPA buffer (not containing protease inhibitors,
sodium deoxycholate and benzonase) and 2× 1 ml lysis
buffer containing 50mMHEPES–KOHpH7.5, 0.1MKCl,
10% glycerol, 2 mMEDTA and 0.1%NP-40. If the samples
were initially lysed in 1× Laemmli, the beads were washed
5× 1 ml RIPA buffer containing 1% Triton X-100, 50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 0.1% SDS, to which PMSF (1 mM) and sodium de-
oxycholate (0.5%) were added immediately before use. After
the final washes, 40 l of 2X Laemmli buffer were added to
the samples, which were then boiled at 100◦C for 8 min to
elute.
Luciferase and Northern blot analysis of reporter mRNA
HeLa cells were lysed 24 h post-transfection in Passive Lysis
Buffer (Promega) and RL and FL activities was measured
using Dual-Luciferase Assay (Promega). For Northern blot
analysis, total RNA was purified on column (BioBasic),
resolved on 1.2% denaturing-agarose gels and transferred
to nitrocellulose membranes. Probes against RL and FL
were generated by PCR, radiolabeled (RadPrime DNA La-
beling System; Thermoscientific) and hybridized. Northern
blots were visualized and quantified by phosphorimaging
(Storm, GE Life Sciences). Representative blots of at least
three replicates are shown.
Recombinant protein purification
The humanMARF1NYNdomain, spanning residues 352–
500, was expressed as a fusion protein containing an N-
terminal Glutathione-S-Transferase (GST) affinity tag fol-
lowed by the human rhinovirus 3C protease cleavage site
and aC-terminal hexahistidine (His6) affinity tag. For struc-
ture determination by X-ray crystallography, two methion-
ine substitutions (I391M/L457M) were introduced into the
DNA sequence of the expression plasmid by site-directed
mutagenesis and verified by Sanger sequencing. The pro-
tein was expressed in Escherichia coli BL21 (DE3) Rosetta
2 (Novagen) cells at 18◦C for 16 h after induction. Cells
were lysed by sonication in lysis buffer (20 mM Tris pH 8.0,
250 mMKCl) supplemented with 1 mMDTT and the clar-
ified lysate was applied to a 5 ml Glutathione Sepharose
4B cartridge (GE Healthcare). Bound protein was eluted
using lysis buffer supplemented with 10 mM reduced glu-
tathione and subsequently dialyzed against lysis buffer in
the presence of 3C protease overnight at 4◦C to cleave the
GST affinity tag. The GST tag was removed by reapplying
the cleaved protein onto a 5 ml Glutathione Sepharose 4B
cartridge. The protein was further purified by size exclusion
chromatography using a Superdex 75 16/600 column (GE
Healthcare) in 20 mM Tris pH 7.5, 150 mM KCl, 1 mM
DTT.
For selenomethionine (SeMet) labeling, the expression of
theMARF1 NYN I391M/L457Mmutant protein was car-
ried out in M9 minimal medium supplemented with 1 g
ml−1 biotin and 1 g ml−1 thiamine. Bacteria were grown
to OD600 of 0.8 followed by the addition of an amino acid
mix (0.1 mg ml−1 Lys, Thr, Phe and 0.05 mg ml−1 Leu,
Ile, Val, SeMet) allowing the incorporation of SeMet. Af-
ter 30 min, the temperature was reduced to 18◦C and ex-
pression was induced by addition of 200 M isopropyl--
D-thiogalactopyranoside (IPTG). Purification of SeMet la-
beled protein was performed as described above.
For in vitro RNA decay assays, wild-type or mutant
(containing tandem alanine substitutions for Asp426 and
Asp427) MARF1 NYN domains, spanning residues 238–
510, were expressed as fusion proteins containing an N-
terminal GST affinity tag followed by the human rhinovirus
3C protease cleavage site. Proteins were expressed in E. coli
BL21 (DE3) Rosetta 2 (Novagen) cells at 37◦C for 4 h after
induction, purified by glutathione sepharose, and cleaved
with HRV 3C Protease (Thermo Scientific) to remove their
GST tags.
Crystallization and Structure determination
The structure of theMARF1NYNdomainwas determined
by a single-wavelength anomalous diffraction (SAD) exper-
iment, exploiting the anomalous diffraction properties of
selenomethionine (SeMet)-substituted MARF1 NYN do-
main I391M/L457M mutant. Following purification, the
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protein was concentrated to 17 mg ml−1 and crystallized
at 20◦C using the hanging drop vapor diffusion method
by mixing equal volumes (1+1 l) of protein with a reser-
voir solution containing 12% (w/v) PEG3350, 0.2 M K3-
Citrate and 0.1 M Bis-Tris propane, pH 6.5. For cryopro-
tection, crystals were transferred into 12% (w/v) PEG3350,
0.2 M K3-Citrate, 0.1 M Bis-Tris propane, pH 6.5, 25%
ethylene glycol and flash-cooled in liquid nitrogen. X-ray
diffraction data were collected at beam line X06DA (PXIII)
of the Swiss Light Source (Paul Scherrer Institute, Villi-
gen, Switzerland). The crystals diffracted to a resolution
of 1.7 A˚, belonged to space group P43212 and contained
two copies of the protein per asymmetric unit. Diffraction
data were processed using XDS (28). Localization of sele-
nium sites, phasing, density modification, and automated
building of a preliminary model was carried out using the
AutoSol routine implemented in Phenix (29). The initial
atomic model was completed by manual building using
COOT (30) and refined using Phenix.Refine (31).
In vitro ribonuclease assay
(U)30 oligonucleotide (IDT) was radiolabelled with a 5′
phosphate using [ -32P] ATP and PNK enzyme (Ther-
moFisher). 3′ end-labeled oligonucleotide (U)30 was pre-
pared using 5-[32P]-pCp and T4 RNA ligase (NEB). La-
belled oligonucleotides were each separated from free nu-
cleotides on mini oligo Quick spin columns (Roche) and
subsequently gel purified. For nuclease assays, 1 MofWT
ormutant recombinantNYN (238–510) was incubatedwith
10 pmol of cold (U)30 RNA, 0.1 pmol of radiolabelled (5′
or 3′) (U)30 in 10 l reaction volumes containing 20 mM
HEPES pH 7.5, 150 mM NaCl, 10% glycerol and 1 mM
DTT. Reactions were also supplemented with 3 mMMnCl2
or 3 mM MgCl2 as described in the figure legends. Reac-
tions were carried out at room temperature for up to 60min.
RNA at each time point was ethanol precipitated and re-
suspended in 10 l loading buffer II (ThermoFisher). Sam-
ples were boiled at 95◦C for 10 min and resolved by elec-
trophoresis on a 15% polyacrylamide and 8 M urea gel and
visualized by phosphorimaging (Storm, GE Life Sciences).
RNA ladderswere prepared by partial alkaline hydrolysis of
5′ end-radiolabeled oligonucleotide (U)30 RNA. This was
performed in a 5 l reaction mixture containing 0.1 pmol
RNA and 66.7 mM (NaHCO3/Na2CO3, pH 9.5) incubated
at 95◦C for 5 min. Reactions were terminated by adding 10
l of loading buffer II (ThermoFisher).
RESULTS
MARF1 physically interacts with the DCP1:DCP2 decap-
ping complex
MARF1 was recently reported to localize to processing (P)
bodies in somatic cells (32) (33). Thus, we set out to iden-
tify MARF1-interacting proteins to determine if MARF1
interacts with any mRNA silencing machineries, including
the CCR4-NOT deadenylase complex and/or factors in-
volved in mRNA decapping and decay that localize to P-
bodies. To this end, FLAG-tagged MARF1 protein was
inducibly expressed from stably-transfected HEK293 cells
and affinity-purified from benzonase-treated cell lysates;
MARF1-bound proteins were subsequently analyzed by
tandem mass spectrometry (MS/MS). Two independent
MARF1 replicates were analyzed, alongside negative con-
trols. Using three different groups of negative controls,
we performed SAINT (Significance Analysis of Interac-
tome) analysis to obtain a list of high-confidence interac-
tions (Figure 1B and Supplementary Table S1) (34). Among
the high-confidence interactors, we found that MARF1 co-
precipitates with a number of mRNA decapping factors
that localize to P-bodies, including enhancers of mRNAde-
capping (EDC3 and EDC4), as well as DCP1 and DCP2.
We also identified PATL1, components of the LSM1-7 com-
plex and the 5′-3′ exonuclease XRN1. In contrast, we did
not detect any subunits of the CCR4-NOT or PAN2-PAN3
deadenylase complexes.
We subsequently performed co-immunoprecipitation
from HEK293 cells expressing either a FLAG-tagged neg-
ative control or FLAG-tagged MARF1 proteins to vali-
date these interactions (Figure 1C through E; note that
the constructs also expresses the biotin ligase BirA*).
Full-length FLAG-BirA*-MARF or FLAG-BirA* were
affinity-purified through the FLAG epitope under mild ly-
sis and wash conditions, and co-immunoprecipitating pro-
teins were eluted from the beads and resolved by SDS-
PAGE followed by western blot analysis (Figure 1D). As in
themass spectrometry experiment, EDC4, PATL1, DCP1A
and DCP2 co-precipitated with MARF1, but CNOT1, the
central subunit of the CCR4-NOT deadenylase complex,
did not. EDC4 has been reported to act as a scaffold upon
which DCP1 activates DCP2 for optimal decapping cat-
alytic activity (35), and was previously reported to associate
with MARF1 (32).
We further validated these results using BioID labeling
coupled to immunoblotting. BioID utilizes an abortive bi-
otin ligase mutant (BirA*) to covalently biotinylate pro-
teins in proximity of BirA*-tagged bait protein, allow-
ing identification of proximal interaction partners in vivo
(PMID: 22412018). For BioID experiments, HEK293 cells
expressing either FLAG-BirA* (control) or FLAG-BirA*-
MARF1 proteins were incubated with biotin for 24 hr and
lysed under harsh conditions to disrupt protein-protein in-
teractions. Biotinylated proteins were subsequently affinity-
purified from benzonase-treated lysates with streptavidin
agarose, eluted and analyzed by western blot using antibod-
ies against a number of P-body proteins (Figure 1E). Con-
sistent with our MS data, FLAG-BirA*-MARF1 biotiny-
lated several mRNA decapping and decay factors, includ-
ing EDC4, PATL1, DCP1, DCP2 and XRN1. In contrast,
FLAG-BirA*-MARF1 did not lead to detectable biotiny-
lation of CNOT1. Taken together, these data suggest that
MARF1 physically interacts with the DCP1:DCP2 mRNA
decapping complex, as well as decapping enhancers and the
5′-3′ exonuclease XRN1, but does not readily associate with
the deadenylase machineries.
The DCP1:DCP2 complex interacts with the MARF1 C-
terminus
Next, we set out to identify which domain ofMARF1 inter-
acts with the DCP1:DCP2 decapping complex. To this end,
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we performed co-immunopreciptiation experiments using
a series of FLAG-tagged MARF1 fragments covering the
entire MARF1 protein (Figure 2A through E). MARF1
fragments containing the isolated NYN, RRM or LOTUS
domains failed to co-precipitate decapping factors (Figure
2C). However, a fragment of MARF1 containing both the
LOTUS domains and the C-terminal 172 amino acids of
MARF1 (LOTUS + C-term) pulled down EDC4, in agree-
ment with a previous report (32), as well as DCP1A, DCP2
and PATL1. In support of these data, we found that a
FLAG-taggedMARF1 protein lacking only the C-terminal
region (C-term) did not interact with decapping factors
(Figure 2D), whereas a FLAG-tagged C-terminal fragment
containing only these 172 residues (C-term) efficiently co-
preciptiated both EDC4 and DCP1 (Figure 2E). Taken to-
gether, these results indicate that MARF1 contains a C-
terminal decapping factor-interaction motif that physically
interacts with theDCP1:DCP2mRNAdecapping complex.
The NYN domain is essential for MARF1-mediated gene si-
lencing
A previous study reported that MARF1 knock-out mouse
oocytes display increased RNA expression of several retro-
transposons, including the LINE1 RNA (15). As MARF1
physically interacts with themRNAdecapping complex, we
next sought to investigate whether MARF1 has the abil-
ity to silence a targeted mRNA. To this end, we took ad-
vantage of the bacteriophage N-BoxB tethering system
in HeLa cells to determine whether MARF1 can silence a
Renilla luciferase (RL) reporter mRNA when tethered to
its 3′UTR (36) (Figure 3A). NHA-tagged MARF1 con-
structs were co-transfected with an RL construct contain-
ing 5 BoxB hairpins in its 3′UTR and a Firefly luciferase
(FL) construct as a transfection control (Figure 3B through
E). Indeed, when full-length NHA-MARF1 was tethered
to the reporter transcript, Renilla luciferase expression was
reduced relative to that in cells expressing the N-peptide
fused to LacZ (Figure 3D). This repression appeared to be
at the level of mRNA expression or stability, as tethering
MARF1 to the reporter mRNA significantly reduced its
levels, as shown by Northern blot analysis (Figure 3D and
E). In contrast to wild-type MARF1, a MARF1 mutant
lacking the NYN domain (MARF1NYN) was unable to ef-
ficiently silence the reporter mRNA.Moreover, the reporter
mRNA remained stable when tethered to MARF1NYN.
Interestingly, a MARF1 mutant lacking the decapping fac-
tor interactionmotif (C-term) silenced a reporter RNA as
well as wild-type MARF1. Taken together, these data sug-
gest that MARF1 post-transcriptionally represses gene ex-
pression by initiating the decay of a targeted mRNA.More-
over, our data suggest that MARF1 requires its NYN do-
main in order to engender the decay of a targeted mRNA.
The MARF1 NYN domain is a bona fide endoribonuclease
The MARF1 NYN domain belongs to a superfamily that
comprises the PIN, NYN and FLAP/5′-3′ exonuclease do-
mains, and includes the eukaryotic Nedd4-binding pro-
teins and bacterial YacP-like nucleases (14,37). The domain
is highly conserved among vertebrates and several insect
species (Figure 4A). To gain structural insights into the
MARF1 NYN domain, we crystallized a human MARF1
protein construct encompassing amino acid residues 352–
500 and determined its structure at a resolution of 1.7 A˚ by
single-wavelength anomalous diffraction (Figure 4B). Al-
though the NYN domain crystallized as a dimer in the
asymmetric unit of the crystal, both the wild-type NYN
domain and the mutated protein used for crystallization
(I391M/L457M) are monomeric in solution, as determined
by size exclusion chromatography (Supplementary Figure
S1). The MARF1 NYN domain consists of a central six-
stranded parallel beta-sheet flanked by pairs of alpha-
helices on both sides, in contrast to the previously deter-
mined structure of the NYN domain of Bacillus subtilis
YacP/Rae1, whose central beta-sheet contains only five
strand (38). Despite lack of extensive sequence conserva-
tion, the MARF1 NYN domain exhibits substantial struc-
tural similarity to canonical PIN domains of ribonucleases
MCPIP1 (39) and SMG6 (40), superimposing with root-
mean-square deviations of 3.0 A˚ (over 96 C atoms) and 3.4
A˚ (94 C atoms), respectively (Figure 4C, D). A prominent
feature of the molecular surface of the MARF1 NYN do-
main is a highly conserved negatively charged patch formed
by Asp358, Asp426, Asp427 and Asp452 (Figure 4B, C).
Similar clusters of acidic amino acids define the active
sites of PIN domain ribonucleases, including SMG6 and
MCPIP1, in which they coordinate a divalent metal ion that
in turn coordinates the substrate RNA and activates a wa-
ter molecule for nucleophilic attack on the scissile phospho-
diester group (39,40). Importantly, these amino acids are
strictly conserved in MARF1 orthologs and map to equiv-
alent residues in the SMG6 and MCPIP1 domain struc-
tures (Figure 4D and Supplementary Figure S2). Crucially
these residues are not present in the SMG5 PIN domain,
which has been shown to lack RNase activity (Supplemen-
tary Figure S2) (40). Together, these structural observations
strongly suggest that theMARF1NYNdomain is a catalyt-
ically competent ribonuclease.
Since theMARF1NYN domain is essential for MARF1
to degrade a reporter RNA in vivo (Figure 3D), it was
pertinent to investigate whether the MARF1 NYN dis-
plays ribonuclease activity. To directly test this, we gener-
ated a recombinantMARF1NYNdomain (NYNWT) (Fig-
ure 5A) and incubated it with a 5′ [32P]-end-labeled single
stranded (U)30 oligonucleotide. The integrity of the RNA
was then analyzed by denaturing polyacrylamide-gel elec-
trophoresis (PAGE) followed by autoradiography (Figure
5B). Our crystal structure revealed that MARF1 contains
a conserved active site pocket that is likely capable of bind-
ing a divalent ion necessary for RNase activity (Figure 4B).
In keeping with these data, purified NYN protein is par-
tially active on its own, but efficiently degrades the single-
stranded oligo in the presence of manganese or magnesium
(Figure 5B). In order to determine whether residues in the
active site pocket are important for NYN enzymatic ac-
tivity, we generated a NYN mutant in which Asp426 and
427 were mutated in tandem to alanines (NYNMUT) (Fig-
ure 5A). The nuclease activity of NYNMUT was strongly re-
duced as compared to NYNWT (Figure 5C). As a number
of PIN domains act as endonucleases (41), we wished to de-
termine if theMARF1NYNdomain displays endonuclease
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Figure 2. TheDCP1:DCP2 complex interacts with theMARF1 C-terminus. (A) Schematic diagram of full-lengthMARF1 andMARF1 fragments used in
co-precipitation experiments in B through E. Dashed lines indicated the region required for decapping factor association in (E). (B) Western blot analysis
of lysates derived from HeLa cells expressing FLAG-tagged MARF1 fragments outlined in (A). (C–E) Immunoprecipitation (IP) of MARF1 fragments
outlined in (A) from benzonase–treated HeLa cell extracts using anti-FLAG antibody. Immunoprecipitated complexes were separated by SDS-PAGE and
probed with antibodies against the indicated proteins. Inputs represent 2% of lysates.
activity. This this end, we incubated recombinant NYNWT
protein with a 3′[32P]-end-labeled (U)30 (Figure 5D), and
observed a similar decay pattern for the 3′ end-labelled oligo
as compared to the 5′ end-labelled RNA. Taken together,
these data suggest that the MARF1 NYN domain is an en-
doribonuclease.
MARF1 NYN domain endonuclease activity promotes
mRNA decay in vivo
To determine if the activity of the NYN domain is re-
quired for MARF1-mediated silencing in vivo, we deleted
(N-termNYN) or mutated (N-termMUT) the NYN domain
in the context of the MARF1 N-terminal fragment and in-
vestigated silencing of the tethered reporter mRNA (Figure
6A–C). Indeed, either deletion of the NYN domain or mu-
tation of aspartates 426 and 427 in the N-terminal MARF1
fragment impaired its ability to silence and degrade a tar-
geted reporter mRNA in vivo.
To ascertain whetherMARF1 promotes mRNA decay in
vivo in a deadenylation-dependent or -independent manner,
we took advantage of a RL-5BoxB reporter that contains
a self-cleaving hammerhead ribozyme (HHR) to generate
an internalized 114 nucleotide poly(A) stretch (Figure 6D)
(42). Importantly, this reporter mRNA can be translation-
ally silenced by the CCR4-NOT deadenylase complex, but
it remains stable because a 3′ stretch of non-A nucleotides
(N40) blocks deadenylation and subsequent decay.We teth-
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Figure 3. MARF1 NYN domain is required to degrade a target mRNA. (A) Schematic diagram of the basic Renilla luciferase-encoding mRNA reporter,
containing five 19-nt BoxB hairpins, interacting with N-HA-MARF1. (B) Schematic diagram of full-length MARF1 and MARF1 fragments used in
tethering assays. (C) Expression levels of NHA-tagged fusion proteins, as determined by western analysis using anti-HA and anti-actin antibodies. (D)
RL activity detected in extracts from HeLa cells expressing the indicated proteins. Cells were cotransfected with constructs expressing the RL-5BoxB
reporter, FL, and indicated fusion proteins. Histograms represented normalized mean values of RL activity and mRNA levels from a minimum of three
experiments. RL activity values seen in the presence of NHA-LacZ were set as 100. (E) Representative Northern blot of RL-5BoxB and FL mRNAs
levels.
ered NHA-tagged full-length MARF1 (MARF1WT) or
a MARF1 deletion mutant lacking the C-terminal decap-
ping factor-interacting motif (MARF1C-term) to this re-
porter and subsequently measured luciferase activity and
reporter mRNA abundance (Figure 6E–G). As a negative
control, we tethered theGW182 silencing domain (GW182-
SD), which interacts with the CCR4-NOT deadenylase
complex has been previously shown to translationally re-
press this reporter mRNA in the absence of deadenylation
and decay (43). Tethering MARF1WT, MARF1C-term or
the GW182-SD to our reporter mRNA resulted in simi-
lar reduction in luciferase activity, as compared to LacZ
tethering (Figure 6F). In agreement with previous reports,
NHA-GW182-SDdid not change the levels of the reporter
mRNA (Figure 6F and G). However, tethering MARF1WT
or MARF1C-term to this reporter mRNA significantly
reduced its levels. These therefore data suggest that the
MARF1 NYN domain displays endoribonuclease activ-
ity, which is able to engender deadenylation-independent
mRNA decay.
DISCUSSION
Here we present data establishing the MARF1 RNA bind-
ing protein an effector of post-transcriptional control and
we shed light upon its mechanism of action. Our proteomic,
structural and biochemical methods as well as functional
assays demonstrate that MARF1 is an endoribonuclease
that interacts with the DCP1:DCP2 complex and brings
about the decay of targeted mRNAs.
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Figure 4. Structure of theMARF1 NYN domain. (A) Comparative sequence analysis of the NYN domains of human (Hs), Xenopus tropicalis (Xt),Danio
rerio (Dr), Lasius niger (Ha) and Apis mellifera (Am) MARF1 orthologs. The multiple sequence alignment was generated using MAFFT version 7 and
formatted using Jalview (49,50). Secondary structure elements with corresponding numbering are indicated above the sequence. Invariant residues are
coloured dark blue while conservative substitutions are depicted in shades of light blue. (B) Left, Crystal structure of the MARF1 NYN domain shown
in cartoon and surface representations. Right, cartoon representation of the MARF1 NYN domain, with invariant active site residues depicted in stick
format. (C) Structural superpositions of the human MARF1 NYN domain with the NYN domain of Bacillus subtilis YacP/Rae1 (PDB 5MQ8), and the
PIN domains of human SMG6 (PDB 2HWW) and MCPIP1 (PDB 3V34). The structures were superimposed using the DALI server (51) and are shown
in identical orientations. (D) Zoom-in view of the NYN domain ribonuclease active site of MARF1, overlaid with the structures of human SMG6 and
MCPIP1 PIN domains. Invariant active site residues are shown in stick format. The bound magnesium ion present in the MCPIP1 structure is depicted as
a purple sphere.
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Figure 5. The MARF1 NYN displays endoribonuclease activity in vitro. (A) Upper panel: Schematic representation of the wild-type and mutant (MUT)
MARF1 NYN proteins used for in vitro degradation assays. Mutant MARF1 protein contains tandem alanine substitutions for Asp426 and Asp427.
Lower panel: Coomassie-stained SDS-PAGE gel of recombinant wild-type (WT) or mutant (MUT) MARF1 NYN proteins. (B) NYNWT protein was
incubated with a 5′-32P-end-labelled U30 oligonucleotide in the presence or absence of 3 mM Mn2+ or Mg2+. RNA was extracted at defined time points
and resolved via denaturing PAGE. RNA signals were visualized by autoradiography. OH: hydrolysis ladder. (C) Time course analysis of NYNWT and
NYNMUT proteins incubated with a 5′-32P-end-labelled U30 oligonucleotide in the presence of Mn2+. OH: hydrolysis ladder. (D) NYNWT protein was
incubated in the presence of Mn2+ with a 3′-32P-end-labelled U30 oligonucleotide. RNA was extracted at defined time points and resolved via denaturing
PAGE. OH: hydrolysis ladder.
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Figure 6. MARF1 NYN displays endonuclease activity in vivo. (A and E) Expression levels of NHA-tagged fusion proteins, as determined by Western
analysis using anti-HA and anti-actin antibodies. (B) RL activity detected in extracts from HeLa cells expressing the indicated proteins. Cells were co-
transfected with constructs expressing the RL-5BoxB reporter, FL, and indicated fusion proteins. Histograms represented normalized mean values of RL
activity and mRNA levels from a minimum of three experiments. RL activity values seen in the presence of NHA-LacZ were set as 100. (C) Represen-
tative Northern blot of RL-5BoxB and FL mRNAs levels for (B). (D) Schematic diagram of the Renilla luciferase-encoding mRNA reporter, containing
five 19-nt BoxB hairpins, a 114 nt internal poly(A), a 40 nt linker and a self-cleaving hammerhead ribozyme (HHR). HHR cleavage site is denoted by an
arrow. (F) Cells were cotransfected with constructs expressing the RL-5BoxB-A114-N40-HHR reporter, FL, and indicated fusion proteins. Histograms
represented normalized mean values of RL activity and mRNA levels from a minimum of three experiments. RL activity values seen in the presence of
NHA-LacZ were set as 100. (G) Representative Northern blot of RL-5BoxB-A114-N40-HHR and FL mRNAs levels for (F).
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MARF1 recruits the DCP1:DCP2 mRNA decapping com-
plex
The major pathway for mRNA turnover in eukaryotes ini-
tiates with removal of the 3′ poly(A) tail by the PAN2-
PAN3 and CCR4-NOT deadenylase complexes (44). This
is followed by hydrolysis of the 5′ cap structure by the
DCP1:DCP2 decapping complex and 5′-3′ decay of the
mRNA body via the XRN1 exonuclease. Multiple RNA
binding or RNA-associated proteins promote mRNA de-
cay of targeted transcripts by physically interacting with
the CCR4-NOT complex to bring about the deadenyla-
tion and subsequent decay of targeted mRNAs. These in-
clude GW182, TTP, YTHDF2, DND1 and Nanos (5,7–
9,45,46). Our results demonstrate that MARF1 also engen-
ders the decay of a target mRNA. However, in contrast
to these RNA binding proteins, our results suggest that
MARF1 physically interacts with the DCP1:DCP2 mRNA
decapping complex rather than with deadenylase machiner-
ies.Mass spectrometry analysis ofMARF1-interacting pro-
teins identified theDCP2 decapping enzyme andDCP1, en-
hancers of mRNA decapping (EDC3 and EDC4), PATL1,
components of the LSM1-7 complex (LSM1 and 2) and the
5′-3′ exonuclease XRN1. These results were validated us-
ing BioID proximity-labeling coupled to immunoblotting
indicating that these interactions exist in vivo, rather than
manifesting post cell lysis. We next show that the distal C-
terminal region of MARF1 acts as the docking site for the
decapping machinery (Figure 2). These data are in agree-
ment with a previous study in which ectopically expressed
EDC4 was found to associate with overexpressed MARF1
(32). However, our data indicate that aMARF1mutant that
does not interact with the decapping machinery also desta-
bilizes a targeted reporter mRNA (Figures 3 and 6), sug-
gesting that the DCP1:DCP2 complex may be recruited in
trans to degrade the 5′ fragment.
The MARF1 NYN domain displays endoribonuclease activ-
ity
MARF1 is critical for generating fertilization-competent
oocytes (15). MARF1 knockout mouse oocytes prema-
turely arrest in meiosis and have been reported to display al-
tered gene expression profiles, including LINE1 retrotrans-
poson accumulation. Here we show that MARF1 post-
transcriptionally represses gene expression by degrading
targeted mRNAs (Figures 3 and 6), and requires it NYN
domain in order to do so. The crystal structure of the
NYN domain shows that it adopts a PIN-like fold that
is structurally similar to that of other endoribonucleases,
including Rae1, MCPIP1/Regnase and SMG6 (Figure 4)
(38,40,47). In agreement with the crystal structure, a recom-
binant MARF1 fragment that includes the NYN domain
displays intrinsic endoribonuclease activity in vitro (Figure
5).
In line with our in vitro degradation experiments,
MARF1 requires its endoribonuclease activity to si-
lence a target mRNA in vivo, as a catalytically inac-
tive MARF1 protein fails to efficiently silence a reporter
mRNA in cells (Figure 6A–C). While many mRNAs de-
cay in a deadenylation-dependent manner (i.e. miRNA
Figure 7. Model of MARF1-mediated mRNA decay. MARF1 binds to
a target mRNA via its RRMs. The MARF1 NYN endonuclease cleaves
the target mRNA, which is subsequently decapped by the DCP1:DCP2
complex and degraded by XRN1 (not shown). Of note, MARF1-binding
sites on targeted mRNAs have yet to be experimentally validated.
targeted mRNAs), our data suggests that MARF1 me-
diates deadenylation-independent mRNA decay (Figure
6D–G). Ultimately, our results support a model whereby
MARF1-targetedmRNAs are first cleaved by theNYNdo-
main, and are subsequently decapped and degraded by the
DCP1:DCP2 decapping complex and XRN1, respectively
(Figure 7).
MARF1 is evolutionarily conserved in vertebrates and
selected insects (Figure 4A). A Drosophila melanogaster
(Dm) MARF1-like protein also exists that contains mul-
tiple LOTUS domains, but lacks a NYN domain (48).
Whether DmMARF1 functions in a similar manner to hu-
man MARF1 remains to be established. The LOTUS do-
mains inMARF1 are also found in other germline proteins,
including Tudor domain containing 5 (TDRD5), TDRD7
and Oskar (48). A recent study showed that the LOTUS do-
mains of TDRD5, TDRD7 and Oskar bind to and stim-
ulate the germline RNA helicase Vasa (48). In contrast,
MARF1 LOTUS domains lack a C-terminal extension
found in TDRD5/7 and Oskar, and do not associate with
Vasa in flies. Thus, the function of theMARF1 LOTUS do-
mains remains elusive. While the LOTUS domains them-
selves do not associate with the decapping machinery, they
may function to orient the DCP1:DCP2 complex towards
the cap structure to facilitate decapping.
In summary, our study identifies MARF1 as an effector
of mRNA decay and provides structural and functional in-
sights into its mode of action. We show thatMARF1 physi-
cally interacts with the DCP1:DCP2 RNA decapping com-
plex and utilizes its PIN-like NYN endonuclease domain
to degrade target mRNAs. In addition to its expression in
the mammalian germline, MARF1 is also expressed in so-
matic tissues, including in the developing cortex where its
expression has been reported to promote neuronal differen-
tiation (16). Importantly, a MARF1 N-terminal truncation
mutant that lacks theNYNdomain could not promote neu-
rogenesis. Taken together with our data, this suggests that
MARF1-mediated mRNAdecay plays an important role in
a number of somatic cell populations.
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